[Coronary thrombolytic agents and their characteristics].
作者信息
Yoshinaga M, Kambara H
机构信息
Cardiovascular Center, Osaka Red Cross Hospital.
出版信息
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):775-81.
PMID:12436615
Abstract
摘要
相似文献
1
[Coronary thrombolytic agents and their characteristics].[冠状动脉溶栓剂及其特性]
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):775-81.
2
[Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].[溶栓剂、尿激酶、组织型纤溶酶原激活剂和尿激酶原——它们的给药途径和剂量：冠状动脉内溶栓与静脉冠状动脉溶栓的比较]
Nihon Rinsho. 2003 Apr;61 Suppl 4:441-5.
3
[Coronary thrombolysis with urokinase and t-PA--comparison of intracoronary thrombolysis and intravenous coronary thrombolysis].[尿激酶和组织型纤溶酶原激活剂进行冠状动脉溶栓——冠状动脉内溶栓与静脉冠状动脉溶栓的比较]
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):782-9.
4
Thrombolytic therapy for acute myocardial infarction--round 2.急性心肌梗死的溶栓治疗——第二轮。
Lancet. 1988 Mar 12;1(8585):565-7.
5
How should intravenous thrombolytic agents for acute myocardial infarction be selected?急性心肌梗死的静脉溶栓药物应如何选择？
Cardiovasc Clin. 1990;21(1):57-75; discussion 76-8.
6
Intra-arterial prourokinase for acute ischemic stroke.急性缺血性卒中的动脉内注射尿激酶原治疗
JAMA. 2000 Apr 26;283(16):2102; author reply 2103-4.
7
The ideal fibrinolytic: can drug design improve clinical results?理想的纤溶药物：药物设计能否改善临床疗效？
Eur Heart J. 1999 Oct;20(20):1452-8. doi: 10.1053/euhj.1999.1659.
8
[Thrombolytic (fibrinolytic) agents for treatment of ischemic heart disease].用于治疗缺血性心脏病的溶栓（纤维蛋白溶解）剂
Nihon Rinsho. 2003 Apr;61 Suppl 4:641-6.
9
[Short- and long-term mortality of intracoronary urokinase in acute myocardial infarction].[急性心肌梗死中冠状动脉内尿激酶的短期和长期死亡率]
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):790-6.
10
[Thrombolytic therapy with tissue-type plasminogen activator].[组织型纤溶酶原激活剂溶栓治疗]
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):797-801.
Zotero 插件